Cargando…

An introduction to insulin use in type 2 diabetes mellitus

The benefits of the newer antidiabetic agents available for managing type 2 diabetes mellitus (T2DM) remain indisputable, but many patients will require insulin therapy in the disease course. Given the limited access to newer antidiabetic agents, insulin remains a standard treatment modality in T2DM...

Descripción completa

Detalles Bibliográficos
Autor principal: Coetzee, Ankia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AOSIS 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157446/
https://www.ncbi.nlm.nih.gov/pubmed/37132569
http://dx.doi.org/10.4102/safp.v65i1.5702
_version_ 1785036754760237056
author Coetzee, Ankia
author_facet Coetzee, Ankia
author_sort Coetzee, Ankia
collection PubMed
description The benefits of the newer antidiabetic agents available for managing type 2 diabetes mellitus (T2DM) remain indisputable, but many patients will require insulin therapy in the disease course. Given the limited access to newer antidiabetic agents, insulin remains a standard treatment modality in T2DM in South Africa. Early, multifactorial intervention remains ideal, but glucose, blood pressure and cholesterol values remain above target in many countries. Barriers to achieving glucose control in South Africa include the healthcare provider’s being unfamiliar with the practicalities of insulin administration, initiation and titration. This article highlights these gaps and offers pragmatic solutions to overcome them.
format Online
Article
Text
id pubmed-10157446
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AOSIS
record_format MEDLINE/PubMed
spelling pubmed-101574462023-05-05 An introduction to insulin use in type 2 diabetes mellitus Coetzee, Ankia S Afr Fam Pract (2004) CPD Article The benefits of the newer antidiabetic agents available for managing type 2 diabetes mellitus (T2DM) remain indisputable, but many patients will require insulin therapy in the disease course. Given the limited access to newer antidiabetic agents, insulin remains a standard treatment modality in T2DM in South Africa. Early, multifactorial intervention remains ideal, but glucose, blood pressure and cholesterol values remain above target in many countries. Barriers to achieving glucose control in South Africa include the healthcare provider’s being unfamiliar with the practicalities of insulin administration, initiation and titration. This article highlights these gaps and offers pragmatic solutions to overcome them. AOSIS 2023-04-20 /pmc/articles/PMC10157446/ /pubmed/37132569 http://dx.doi.org/10.4102/safp.v65i1.5702 Text en © 2023. The Authors https://creativecommons.org/licenses/by/4.0/Licensee: AOSIS. This work is licensed under the Creative Commons Attribution License.
spellingShingle CPD Article
Coetzee, Ankia
An introduction to insulin use in type 2 diabetes mellitus
title An introduction to insulin use in type 2 diabetes mellitus
title_full An introduction to insulin use in type 2 diabetes mellitus
title_fullStr An introduction to insulin use in type 2 diabetes mellitus
title_full_unstemmed An introduction to insulin use in type 2 diabetes mellitus
title_short An introduction to insulin use in type 2 diabetes mellitus
title_sort introduction to insulin use in type 2 diabetes mellitus
topic CPD Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157446/
https://www.ncbi.nlm.nih.gov/pubmed/37132569
http://dx.doi.org/10.4102/safp.v65i1.5702
work_keys_str_mv AT coetzeeankia anintroductiontoinsulinuseintype2diabetesmellitus
AT coetzeeankia introductiontoinsulinuseintype2diabetesmellitus